ImmunoCellular Therapeutics, Ltd Provides an Update on Enrollment for the Company’s Phase II Clinical Trial

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company’s dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM). The Company has initiated the trial in 25 sites, with patients enrolled in leading medical centers such as Mass General Cancer Center and the Dana Farber Cancer Institute. The trial is expected to enroll approximately 200 or more patients to treat 102 patients with HLA-A1/A2 immunological subtypes. There are 189 patients enrolled in the study to date, and enrollment is expected to be completed by the second quarter of 2012.